Vasculitides comprise a heterogeneous group of disorders characterised by inflammation and necrosis of the walls of arteries and veins of different calibres supplying various body districts. Symptoms include signs of local and systemic inflammation and secondary symptoms arising from reduced tissue perfusion.
The term “ANCA-associated systemic vasculitides” (AAV), recognised by the Chapel Hill Consensus Conference, identifies primary vasculitides with similar clinical and pathological features in which antibodies to neutrophil cytoplasmic constituents are frequently detected.
AAVs are classified into three main forms, based on clinical phenotype and ANCA subtype:
- Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis)
- Microscopic polyangiitis (MPA)
- Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg–Strauss syndrome)
The detection of ANCA-PR3 and/or ANCA-MPO in patients with symptoms suggestive of vasculitis has a very high positive predictive value. The presence of anti-MPO antibodies is mainly associated with microscopic polyangiitis. These antibodies may also be found in polyarteritis nodosa, eosinophilic granulomatosis with polyangiitis and Goodpasture syndrome.
Serum, EDTA plasma, heparin plasma, citrate plasma*
* ELISA and immunoblot tests only
ELISA, immunoblot, ChLIA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.